GlycoMimetics, Inc. GLYC was a big mover last session, as the company saw its shares skyrocketed to almost 99% on the day. The upside occurred after the company declared that the FDA designated one of its drugs as a Breakthrough Therapy. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up almost 134% in the past one-month time frame.
The company has seen one positive and negative estimate revisions in the past seven days. Also, its Zacks Consensus Estimate moved higher over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
GlycoMimetics currently carries a Zacks Rank #3 (Hold).
GlycoMimetics, Inc. Price
GlycoMimetics, Inc. Price | GlycoMimetics, Inc. Quote
A top-ranked stock in the Medical-Drugs industry is Aerie Pharmaceuticals, Inc. AERI sporting a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is GLYC going up? Or down? Predict to see what others think: Up or Down
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Click for Free GlycoMimetics, Inc. (GLYC) Stock Analysis Report >>
Click for Free Aerie Pharmaceuticals, Inc. (AERI) Stock Analysis Report >>
To read this article on Zacks.com click here.
Zacks Investment Research